Due to the different mutation profiles of the cells used, and the fact that BRAF mutated cells (RKO) responded better to VPE than KRAS mutated cells (HCT116), also in combination treatments with 5-FU, our results suggest that patients with colorectal tumors harboring BRAF mutations would benefit most from combination treatments VPE+5-FU, compared with patients with tumors harboring KRAS mutations. Here, KRAS is linked to colorectal neoplasm.